Company intelligence / Profile preview

Variantyx

Framingham, Massachusetts, United Statesvariantyx.com ↗

Ownership: Private
Employees: ~150
Development stage: Commercial

Overview

Variantyx offers advanced, clinically accredited whole genome sequencing-based diagnostic tests for rare genetic disorders, reproductive health, and precision oncology. Their proprietary technology enables high diagnostic yield, rapid turnaround times, and comprehensive detection of genomic alterations missed by traditional methods. The company has sequenced tens of thousands of genomes to date and continues to innovate in the field with new technologies such as combined short-read/long-read sequencing for expanded detection capabilities.

Therapeutic areas: OncologyRare DiseasesWomen's Health
Modalities: Diagnostic testGenomic testing (Whole genome sequencing)AI/ML-based analysis tools
Industry: Molecular Diagnostics

Beyond the preview

Go deeper on Variantyx.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Variantyx.

Explore the full profile